Behind Haier Financial Holdings' Rumor Clarification, the Investigation into Wenhong and Her "Blood Replacement Anti-Aging" | Big Fish Finance

Why did AI · Haier Financial Holdings urgently deny cooperation with Yu Meiren?

On March 30, 2026, Haier Financial Holdings issued a statement through its health ecosystem brand “Yingkang Yisheng,” explicitly denying any form of cooperation between its subsidiaries and Yu Wenhong and the medical aesthetic brand “Yu Meiren,” while emphasizing that they have never engaged in businesses such as “blood microvesicle extraction, blood exchange therapy,” and other related activities.

This statement was directly triggered by several videos circulating online recently. In the videos, Yu Wenhong, founder of Yu Meiren International Group, is seen promoting some highly expensive “rejuvenation” projects to agents, with single-session prices ranging from 1.5 million to 20 million yuan. She claims these projects are operated through “tripartite cooperation,” involving Haier Group and Pengruili Group.

The frequently appearing scene in the videos is the Chengdu Xunshang Pengruili Hospital, indirectly invested by Haier’s “Yingkang Future.” On one hand, it is a “cutting statement” carefully crafted by a Fortune 500 company; on the other hand, the personnel involved have been openly recruiting and promoting within the hospital for nearly two years. This discrepancy has attracted public attention.

Investigative reporters from Xinhuanghe have analyzed business registration information to try to restore the true operational status behind this joint venture hospital, and how a business entity that had been penalized multiple times for violations gradually entered this modern medical building.

Past controversies of Yu Wenhong: From 11 square meters to a 4.7 billion yuan tax evasion scandal

In her public narrative, Yu Wenhong is portrayed as a self-made inspiring woman. In 1992, in her early twenties, she started her entrepreneurial journey in Dalian from a small beauty workshop of less than 11 square meters. Over more than thirty years, her “Yu Meiren” brand has grown into a medical aesthetic enterprise with dozens of offline clinics. Data from Tianyancha shows she has 46 related companies under her name.

However, beyond her rapid business expansion, regulatory and judicial records tell a different story.

In 2011, CCTV’s “Focus Interview” reported on Yu Wenhong, pointing out that she performed plastic surgery without a licensed physician, causing facial damage to consumers and ineffective repairs. The report also revealed her early customer acquisition methods: cooperating with grassroots beauty salons and hair salons across various regions, which provided paying clients, with profits shared. This approach—using local beauty salons as channels to select high-net-worth clients—remained largely unchanged over the next two decades.

From early “beauty salon referrals + profit sharing” to recent training, agency, and recruitment expansion, her business structure has consistently shown channel-driven characteristics. Dependence on terminal stores and intermediary agents has become a key continuity across different business phases.

A civil judgment from Hangzhou Intermediate People’s Court also documented the true situation of her early business model. The ruling shows that in 2005, Yu Wenhong, under the name of a person responsible for “Yu Meiren,” promoted “Golden Thread Beauty” surgery. Although the case was ultimately dismissed for insufficient evidence, the court found that she had showcased this consumer as a “success story” at promotional events and had an agreement with her (then a beauty shop owner) that customers doing “Golden Thread Beauty” in her shop would share profits at a 7:3 ratio until the project was halted in early 2006 after being exposed by authorities.

Since then, the Yu Meiren system has repeatedly crossed regulatory red lines. In 2022, Hangzhou tax authorities reported that companies controlled by Yu Wenhong had concealed over 8B yuan in income over five years, amounting to tax evasion, with fines exceeding 88 million yuan.

In 2023, her organization was fined 2 million yuan for illegal medical advertising and price fraud during live broadcasts. In 2024, her brother publicly offered a reward of 4.76B yuan for clues about her violations. In early 2026, she was court-ordered to publicly apologize for online defamation.

Such a business entity with multiple public violations in compliance quietly entered the Chengdu Xunshang Pengruili Hospital, backed by Haier and Pengruili’s joint venture, and attempted to use this hospital as an important external platform for her business.

Dangerous “anti-aging” business: the compliance doubts behind “blood exchange” and distribution

After entering this hospital, what exactly is Yu Wenhong’s team selling? Several leaked internal presentation videos provide direct insight, revealing content far beyond conventional medical scope.

In the videos, Yu Wenhong repeatedly introduces a technology called “microvesicle extraction” to agents in the first person. She explains that these “microvesicles” come from “males aged 17 to 21,” and says “each person only has a tiny amount, requiring many people to gather for use.” She also claims this technology “has approval from the Ministry of Health,” with single-session charges ranging from 1.5 million to 20 million yuan.

Some leaked promotional clips also mention that the blood source “originally used in clinical transfusion systems,” implying a connection to formal medical channels. These claims cannot be independently verified at present, but under current regulatory frameworks, blood collection, circulation, and use in China are strictly restricted. Any commercial operation outside clinical use is highly sensitive.

In fact, reviewing multiple leaked internal videos shows that Yu Wenhong promoting “blood exchange” and “microvesicles” is not recent; the earliest circulating videos date well before 2025. This indicates that this controversial business had already been brewing and recruiting within the joint hospital system long before.

To prove the legality of her raw material sources, Yu Wenhong even claimed in videos: “We bought a blood product pharmaceutical factory to find this raw material, which is a listed company worth hundreds of billions.” This statement is widely interpreted as an allusion to Haier’s related mergers and acquisitions. Public information shows Haier Bio participated in acquiring Shanghai Laisi, a listed company on A-shares, but that transaction has no connection to Yu Meiren. This discrepancy triggered Haier’s urgent clarification.

Regarding the medical effects claimed, such as “women can still menstruate at 75,” some medical professionals expressed caution. A chief gynecologist from a tertiary hospital stated that externally stimulating bleeding is not normal menstruation and could induce endometrial disease. Several clinicians confirmed that plasma exchange is a strictly regulated clinical technique, and using it as a routine anti-aging commercial method involves significant compliance and safety risks.

Additionally, Yu Wenhong’s team cited Silicon Valley entrepreneur Bryan Johnson, claiming he “personally experienced whole blood exchange therapy at this hospital and confirmed its effectiveness.” However, the Xinhuanghe reporter found no evidence of any connection between him and this hospital in publicly available medical records.

In terms of business model, its underlying logic has also attracted attention. In another promotional video, Yu Wenhong explicitly stated: “Mainland China only allows two-tier profit sharing; anything beyond that is illegal, but we want to do multi-layer,” and mentioned using offshore structures, such as operations in Malaysia.

Domestically, her promoted “Vita滴” intravenous injection project is targeting recruitment across beauty salons nationwide. Industry insiders specializing in medical compliance pointed out that such formulas fall under the category of self-made preparations by medical institutions, which require obtaining a “Medical Institution Preparation License.” Unauthorized preparation could face legal risks. To address franchisees’ concerns, Yu Wenhong assured at recruitment events: “All medical responsibilities are mine… you make money, I will bear the responsibility.” The legal representative and other key roles in this project are held by Li Dale, legal representative of Chengdu Xunshang Pengruili Hospital.

Key figures’ “dual identities” and a 37-day time gap

The high-priced projects promoted by Yu Wenhong to agents are mainly backed by the Chengdu Xunshang Pengruili Hospital. The key person enabling her to smoothly enter this hospital system is Li Dale.

Public records show Li Dale holds multiple identities in different contexts. In official collaborations and academic settings, he appears as a compliant medical manager. Between 2023 and 2026, his titles switch between “Medical Director” and “Chief Executive Officer.”

Tianyancha data indicates that most core companies of the Xunshang group were only registered between 2022 and 2023, and Li Dale’s ultimate beneficial ownership in the controlling company Xunshang Technology (Hainan) is only 2.7%. In internal sales contexts of Yu Meiren, his image is described by service providers as a “rich second-generation, celebrity husband” catering to lower-tier markets.

Ownership transparency shows that the major shareholder of Chengdu Xunshang Pengruili Hospital is Xunshang Technology (Hainan) (holding 60%), while Haier’s Yingkang Future holds 40% of Xunshang Technology (Hainan), making it an important indirect investor. The hospital held an official opening ceremony on June 26, 2023. Just 37 days later, on August 2, 2023, Yu Wenhong and her team appeared at the hospital for a ribbon-cutting event.

Images from the scene show that the flower baskets at the entrance bore the inscription “Yu Meiren Xunshang Pengruili Hospital”—a name not registered with the industrial and commercial bureau, directly linking the two brands. Li Dale also appeared alongside Yu Wenhong at the hospital’s opening ceremony.

Subsequently, this compliant image was widely used in commercial promotions. Some public recruitment and marketing materials claimed “backed by two Fortune 500 companies” to attract attention. In a video released in late March 2026, Yu Wenhong’s core disciple publicly showcased the hospital’s exterior and interior, claiming: “We have a 60k-square-meter hospital in Chengdu, with daily inspections by various regulatory departments!” This public statement starkly contrasts with their own claims of compliance.

Terminal controversies and giant brands distancing themselves: how are Fortune 500 brands being overdrawn?

On social media platforms, numerous recruitment accounts tagged with “Yu Meiren” reveal the actual operation at the end of this system.

A self-proclaimed “disciple of Yu Wenhong” posted numerous short videos claiming “spent over 8B on plastic surgery,” and told viewers that the way to make money is “doing the rich man’s business with my master, each deal starts at 5 million.” This method of attracting agents through showcasing huge consumption has raised doubts among some netizens about the “beauty marks” of the claimed medical effects.

It is noteworthy that in some public speeches and training materials, Yu Wenhong also strongly questioned popular market projects like “stem cell transfusion,” citing compliance risks. Yet, in the same context, her team promoted “Vita滴” intravenous injection products. This simultaneous emphasis on others’ risks and promotion of her own alternatives is seen by some industry insiders as a typical sales strategy.

Many consumers posted on social platforms that during basic skincare at beauty salons, they encountered prolonged Yu Meiren project pitches, with some being asked to pay additional “operation fees” and “file fees.”

In some recruitment materials and practitioner exchanges, besides these fees, there are also arrangements for project-based sharing or tiered profit sharing. Coupled with their past channel-based business model, such fee structures are considered closer to a “project-based sales system” rather than traditional single medical service charges.

The Yu Meiren team’s use of Fortune 500 companies as marketing and recruitment endorsements ultimately drew widespread public attention, prompting Haier Financial Holdings to urgently issue a “never collaborated” clarification on March 30.

Haier Financial Holdings clarified that it has no relationship with Yu Meiren in terms of equity or direct business. From the corporate structure perspective, Haier’s joint ventures are with Xunshang Technology and Li Dale; Yu Wenhong does not appear on the shareholder list.

Over more than two years, Yu Wenhong’s team continued to hold business activities within the joint hospital and publicly released recruitment promotions bearing the hospital’s name and “Fortune 500” branding nationwide. On March 30, a reporter called Chengdu Xunshang Pengruili Hospital and was told by staff that Yu Wenhong “is the president” and “often at the hospital,” mentioning plasma exchange and other “rejuvenation” projects.

As a major investor holding 40% of the hospital’s shares (Xunshang Technology), Yingkang Future did not directly operate the hospital’s business initially, but there were regulatory blind spots in due diligence and long-term compliance management. Over more than two years, commercial activities persisted within the joint hospital, with the involved team repeatedly promoting the “joint hospital” and “Fortune 500 background” as core external branding. This brand association and market perception have long exceeded the scope of corporate ownership and have caused the giant’s brand reputation to be long exploited and overdrawn.

Reporter: Du Lin Editor: Cao Mengjia Proofreading: Liu Tian